MedTrace Logo

Study of Influence of Atorvastatin on the Repolarisation Phase of Cardiomyocytes

NCT00520585 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL

Last updated 2007-08-24

No results posted yet for this study

Summary

The aim of this study is to evaluate influence of atorvastin on the repolarisation phase of cardiomyocytes. If there is any, it could be a part of positive "non-lipid" effect of statins in therapy of ischaemic heart disease.

Study hypothesis: atorvastin will decrease heterogeneity of repolarisation of cardiomyocytes in comparison with placebo

Conditions

  • Heterogeneity of Cardiomyocytes Repolarisation
  • Autonomic Changes of Cardiomyocytes Repolarisation

Interventions

DRUG

atorvastatin

atorvastatin 20 mg once vs. atorvastatin 80 mg once vs. placebo

Sponsors & Collaborators

  • Masaryk University

    lead OTHER

Principal Investigators

  • Ondrej Toman, MD · University Hospital Brno, Department of Cardiology, Brno, Czech Republic

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-08-31
Completion
2007-11-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00520585 on ClinicalTrials.gov